Clinical data | |
---|---|
Trade names | Conflictan |
Other names | CERM-1766 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.043.490 |
Chemical and physical data | |
Formula | C14H18F3NO |
Molar mass | 273.299 g·mol−1 |
3D model (JSmol) | |
|
Oxaflozane (INN) (brand name Conflictan) is an antidepressant and anxiolytic drug that was introduced by Solvay in France in 1982 for the treatment of depression but has since been discontinued.[1][2][3][4] It is a prodrug of flumexadol (N-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an agonist of the serotonin 5-HT1A (pKi = 7.1) and 5-HT2C (pKi = 7.5) receptors and, to a much lesser extent, of the 5-HT2A (pKi = 6.0) receptor.[4][5] In addition to its serotonergic properties, oxaflozane may also produce anticholinergic side effects at high doses, namely in overdose.[6]